MedTrace Logo

Medical Cannabis Registry and Pharmacology

NCT03699527 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2020-01-27

No results posted yet for this study

Summary

The overall goals of this research is to describe the 1) natural history of current use and disposition of medical cannabis products including Cannabidiol (CBD) products, being administered to children as standard of care for the treatment of Autism Spectrum Disorder (ASD), 2) understand the pharmacokinetic and pharmacodynamics of medical cannabis products and 3) provide educational feedback on what is learned to families and care providers to provide evidenced based dosing guidance for these products to the pediatric community.

Conditions

Interventions

BEHAVIORAL

Multiple questionnaires administered

This is an observational trial

Sponsors & Collaborators

Principal Investigators

  • Athena Zuppa, MD, MSCE · Children's Hospital of Philadelphia

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-15
Primary Completion
2020-01-15
Completion
2020-01-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03699527 on ClinicalTrials.gov